Clinical Trial Update: NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating the NALIRIFOX regimen (nal-IRI plus 5-FU/LV plus oxaliplatin) as first-line therapy for advanced small intestine and ap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Appendiceal Cancer
• Small Intestine Cancer

Drugs mentioned

• 5-FU (5-fluorouracil) (5-fluorouracil)
• Leucovorin (folinic acid)
• Nal-IRI (liposomal irinotecan) (liposomal irinotecan)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: Advanced Small Intestine Cancer, Appendiceal Cancers | Phase 1 | Status: NOT_YET_RECRUITING